NIH Awards $26K Standing Order for Reagents to QuidelOrtho Sales Company, LLC
Contract Overview
Contract Amount: $26,216 ($26.2K)
Contractor: Quidelortho Sales Company, LLC
Awarding Agency: Department of Health and Human Services
Start Date: 2026-04-10
End Date: 2026-09-30
Contract Duration: 173 days
Daily Burn Rate: $152/day
Competition Type: COMPETED UNDER SAP
Number of Offers Received: 1
Pricing Type: FIRM FIXED PRICE
Sector: Healthcare
Official Description: 26-003839 6 MONTH STANDING ORDER FOR REAGENTS
Place of Performance
Location: SAN DIEGO, SAN DIEGO County, CALIFORNIA, 92121
Plain-Language Summary
Department of Health and Human Services obligated $26,216.26 to QUIDELORTHO SALES COMPANY, LLC for work described as: 26-003839 6 MONTH STANDING ORDER FOR REAGENTS Key points: 1. Spending is minimal ($26K) for a 6-month period. 2. Competition method is 'COMPETED UNDER SAP', suggesting a streamlined process. 3. The contract is for In-Vitro Diagnostic Substance Manufacturing. 4. Risk appears low due to the small contract value and defined period.
Value Assessment
Rating: good
The contract value of $26,216.26 for a 6-month standing order of reagents appears reasonable given the specialized nature of in-vitro diagnostics. Benchmarking against similar, smaller-scale reagent procurements would provide further validation.
Cost Per Unit: N/A
Competition Analysis
Competition Level: limited
The contract was competed under SAP (Simplified Acquisition Procedures), indicating a competitive process for smaller dollar amounts. This method aims for efficiency but may not achieve the same price discovery as full and open competition.
Taxpayer Impact: The taxpayer impact is minimal due to the low contract value of $26,216.26.
Public Impact
Ensures availability of critical diagnostic reagents for NIH research. Supports ongoing public health research and development efforts. Facilitates timely access to necessary laboratory supplies.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Potential for price increases in future renewals.
- Reliance on a single vendor for critical supplies.
Positive Signals
- Supports critical research infrastructure.
- Utilizes a streamlined acquisition process.
Sector Analysis
The procurement falls within the healthcare and life sciences sector, specifically for in-vitro diagnostic substances. Spending benchmarks for reagents vary widely based on type and volume, but this contract's value is modest.
Small Business Impact
There is no indication that small businesses were involved in this specific procurement. Further analysis would be needed to determine if opportunities were missed or if the vendor is a large business.
Oversight & Accountability
The contract was awarded via Purchase Order under SAP, which typically involves less extensive documentation and oversight than larger contracts. Standard procurement regulations likely apply.
Related Government Programs
- In-Vitro Diagnostic Substance Manufacturing
- Department of Health and Human Services Contracting
- National Institutes of Health Programs
Risk Flags
- Limited competition due to SAP.
- Potential for price escalation in future.
- Vendor lock-in for critical supplies.
Tags
in-vitro-diagnostic-substance-manufactur, department-of-health-and-human-services, ca, purchase-order, under-100k
Frequently Asked Questions
What is this federal contract paying for?
Department of Health and Human Services awarded $26,216.26 to QUIDELORTHO SALES COMPANY, LLC. 26-003839 6 MONTH STANDING ORDER FOR REAGENTS
Who is the contractor on this award?
The obligated recipient is QUIDELORTHO SALES COMPANY, LLC.
Which agency awarded this contract?
Awarding agency: Department of Health and Human Services (National Institutes of Health).
What is the total obligated amount?
The obligated amount is $26,216.26.
What is the period of performance?
Start: 2026-04-10. End: 2026-09-30.
What is the typical unit cost for these reagents under similar contracts?
Determining the typical unit cost for these specific reagents under similar contracts is challenging without detailed product information and access to historical pricing data. However, given the $26,216.26 total for six months, the agency likely secured competitive pricing through the SAP process. Future analysis could involve requesting itemized pricing from the vendor or comparing with publicly available catalog prices for similar diagnostic substances.
What is the risk of supply chain disruption for these reagents?
The risk of supply chain disruption for these reagents is moderate. While QuidelOrtho is a known supplier, reliance on a single vendor for a standing order introduces vulnerability. The short 6-month duration mitigates some risk, but the agency should monitor market conditions and consider alternative suppliers for future procurements to ensure continuity of operations.
How effective is the SAP competition method for ensuring value in reagent procurement?
The effectiveness of the SAP competition method for ensuring value in reagent procurement is generally considered good for smaller dollar amounts like this $26K contract. SAP streamlines the process, reducing administrative burden and potentially leading to faster delivery. However, it may not always yield the absolute lowest price compared to full and open competition, especially for highly specialized or high-volume items.
Industry Classification
NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › In-Vitro Diagnostic Substance Manufacturing
Product/Service Code: INSTRUMENTS AND LABORATORY EQPT
Competition & Pricing
Extent Competed: COMPETED UNDER SAP
Solicitation Procedures: SIMPLIFIED ACQUISITION
Solicitation ID: 26-003839
Offers Received: 1
Pricing Type: FIRM FIXED PRICE (J)
Evaluated Preference: NONE
Contractor Details
Address: 9975 SUMMERS RIDGE RD, SAN DIEGO, CA, 92121
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Limited Liability Corporation, Not Designated a Small Business, Special Designations, U.S.-Owned Business
Financial Breakdown
Contract Ceiling: $26,216
Exercised Options: $26,216
Current Obligation: $26,216
Contract Characteristics
Commercial Item: COMMERCIAL PRODUCTS/SERVICES
Timeline
Start Date: 2026-04-10
Current End Date: 2026-09-30
Potential End Date: 2026-09-30 00:00:00
Last Modified: 2026-04-10
More Contracts from Quidelortho Sales Company, LLC
- Lease of Ortho Vision and Reagents — $838.5K (Department of Veterans Affairs)
- ::blood Bank Analyzer:: — $172.7K (Department of Veterans Affairs)
- Blood Bank Testing Quality Control for Boise VA Medical Center — $66.1K (Department of Veterans Affairs)
- Blook Bank Testing Supplies — $45.2K (Department of Veterans Affairs)
- Quidelorthro Triage Meterpro Reagents and Supplies — $40.8K (Department of Veterans Affairs)
Other Department of Health and Human Services Contracts
- Contact Center Operations (CCO) — $5.5B (Maximus Federal Services, Inc.)
- TAS::75 0849::TAS Oper of Govt R&D Goco Facilities — $4.8B (Leidos Biomedical Research Inc)
- THE Purpose of This Contract IS to Provide the Full Complement of Services Necessary to Care for UC in ORR Custody Including Facilities Set-Up, Maintenance, and Support Internal and Perimeter (IF Applicable) Security, Direct Care and Supervision Inc — $3.5B (Rapid Deployment Inc)
- Contact Center Operations — $2.6B (Maximus Federal Services, Inc.)
- Federal Contract — $2.4B (Leidos Biomedical Research Inc)
View all Department of Health and Human Services contracts →